Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Empliciti
Empliciti
2 newer multiple myeloma drugs fall short in bid for wider market
2 newer multiple myeloma drugs fall short in bid for wider market
BioPharma Dive
Multiple Myeloma
clinical trials
Bristol-Myers Squibb
Takeda
Ninlaro
Empliciti
Revlimid
Flag link:
Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Endpoints
Bristol-Myers Squibb
Celgene
M&A
clinical trials
Multiple Myeloma
Empliciti
AbbVie
Revlimid
Flag link:
Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen
Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen
Endpoints
Bristol-Myers Squibb
AbbVie
Empliciti
Celgene
Europe
relapsed or refractory multiple myeloma
Flag link:
Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myeloma
Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myeloma
Fierce Pharma
Bristol-Myers Squibb
AbbVie
Empliciti
FDA
Multiple Myeloma
Celgene
Pomalyst
Flag link:
Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review
Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review
Yahoo/Zacks.com
Bristol-Myers Squibb
Empliciti
Celgene
Pomalyst
Multiple Myeloma
Flag link:
Bristol-Myers, AbbVie eye new use for myeloma drug Empliciti after phase 2 combo win
Bristol-Myers, AbbVie eye new use for myeloma drug Empliciti after phase 2 combo win
Fierce Pharma
Bristol-Myers Squibb
AbbVie
Empliciti
Multiple Myeloma
Flag link:
Amgen's Kyprolis stands its ground against new J&J, BMS rivals
Amgen's Kyprolis stands its ground against new J&J, BMS rivals
Fierce Pharma
Amgen
Kyprolis
JNJ
Bristol-Myers Squibb
Multiple Myeloma
Darzalex
Empliciti
AbbVie
Takeda
Ninlaro
Flag link:
New myeloma meds work better than the old, but they're far too expensive: Report
New myeloma meds work better than the old, but they're far too expensive: Report
Fierce Biotech
Multiple Myeloma
Bristol-Myers Squibb
Amgen
Takeda
Empliciti
Kyprolis
Ninlaro
Celgene
Revlimid
Flag link:
Bristol Myers’s Empliciti Receives FDA Approval
Bristol Myers’s Empliciti Receives FDA Approval
Yahoo/Market Realist
Bristol-Myers Squibb
Empliciti
FDA
Multiple Myeloma
Flag link:
Can Bristol-Myers Squibb And AbbVie's Empliciti Become a Top Seller?
Can Bristol-Myers Squibb And AbbVie's Empliciti Become a Top Seller?
Motley Fool
AbbVie
Bristol-Myers Squibb
Empliciti
Multiple Myeloma
Flag link:
Will Bristol-Myers (BMY) Stock Be Helped by Myeloma Gaining FDA Priority Review Approval?
Will Bristol-Myers (BMY) Stock Be Helped by Myeloma Gaining FDA Priority Review Approval?
TheStreet.com
Bristol-Myers Squibb
priority review
FDA
Multiple Myeloma
Empliciti
Flag link: